Incyte Corp Ltd (INCY): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Incyte ( INCY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.1%. By the end of trading, Incyte rose $1.67 (3.6%) to $47.82 on average volume. Throughout the day, 1,821,844 shares of Incyte exchanged hands as compared to its average daily volume of 1,716,200 shares. The stock ranged in a price between $45.77-$48.40 after having opened the day at $46.35 as compared to the previous trading day's close of $46.15. Other companies within the Drugs industry that increased today were: Enanta Pharmaceuticals ( ENTA), up 28.6%, Relypsa ( RLYP), up 16.6%, Acceleron Pharma ( XLRN), up 9.8% and Xencor ( XNCR), up 9.6%.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $7.5 billion and is part of the health care sector. Shares are up 177.8% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Incyte a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally high debt management risk.

On the negative front, Mast Therapeutics ( MSTX), down 42.9%, TG Therapeutics ( TGTX), down 10.5%, NuPathe ( PATH), down 10.4% and Cyclacel Pharmaceuticals ( CYCC), down 10.4% , were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens